Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
$15.00
+4.7%
$14.30
$10.57
$33.33
$2.08B1.331.14 million shs2.02 million shs
Indivior PLC stock logo
INDV
Indivior
$15.14
-0.2%
$12.94
$7.33
$15.88
N/A0.651.23 million shs1.17 million shs
Organogenesis stock logo
ORGO
Organogenesis
$4.46
-3.7%
$3.54
$2.28
$6.71
$587.33M1.71.14 million shs743,390 shs
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
$5.59
+4.3%
$4.82
$3.79
$12.36
$2.18B0.9116.33 million shs34.34 million shs
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
+4.68%+0.67%+2.39%+20.00%-28.44%
Indivior PLC stock logo
INDV
Indivior
-0.20%-1.69%+12.73%+69.35%+48.58%
Organogenesis stock logo
ORGO
Organogenesis
-3.67%+10.12%+29.65%+18.93%+60.43%
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
+4.29%+7.29%+4.10%+23.95%-24.87%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
4.5778 of 5 stars
4.52.00.04.72.62.50.0
Indivior PLC stock logo
INDV
Indivior
2.6274 of 5 stars
2.63.00.00.01.91.71.9
Organogenesis stock logo
ORGO
Organogenesis
4.3359 of 5 stars
3.03.00.04.31.94.20.6
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
1.9534 of 5 stars
3.21.00.00.02.61.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
3.06
Buy$33.71124.76% Upside
Indivior PLC stock logo
INDV
Indivior
3.25
Buy$17.0012.29% Upside
Organogenesis stock logo
ORGO
Organogenesis
2.00
Hold$6.0034.53% Upside
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
2.33
Hold$7.0025.22% Upside

Current Analyst Ratings Breakdown

Latest ORGO, RXRX, DNLI, and INDV Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/8/2025
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$8.00
7/3/2025
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageEqual Weight$5.00
6/30/2025
Indivior PLC stock logo
INDV
Indivior
Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$15.00 ➝ $22.00
6/16/2025
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$8.00 ➝ $5.00
5/19/2025
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$28.00 ➝ $27.00
5/8/2025
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$30.00 ➝ $29.00
5/7/2025
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$32.00 ➝ $30.00
5/7/2025
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$80.00 ➝ $32.00
5/6/2025
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$11.00 ➝ $8.00
4/24/2025
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
4/10/2025
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Overweight
(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
$330.53M6.59N/AN/A$8.53 per share1.76
Indivior PLC stock logo
INDV
Indivior
$1.19BN/A$1.82 per share8.33($2.52) per shareN/A
Organogenesis stock logo
ORGO
Organogenesis
$482.04M1.17$0.20 per share22.19$2.09 per share2.13
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
$58.84M38.62N/AN/A$2.61 per share2.14
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
-$422.77M-$2.67N/AN/AN/AN/A-35.90%-32.41%7/30/2025 (Estimated)
Indivior PLC stock logo
INDV
Indivior
$2M-$0.31N/A8.85N/A-4.02%-97.29%15.74%7/24/2025 (Estimated)
Organogenesis stock logo
ORGO
Organogenesis
$860K-$0.17N/AN/AN/A-3.46%-4.00%-2.26%8/6/2025 (Estimated)
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
-$463.66M-$1.77N/AN/AN/A-961.32%-74.70%-54.02%8/6/2025 (Estimated)

Latest ORGO, RXRX, DNLI, and INDV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
-$0.73N/AN/AN/AN/AN/A
7/24/2025Q2 2025
Indivior PLC stock logo
INDV
Indivior
$0.25N/AN/AN/AN/AN/A
5/8/2025Q1 2025
Organogenesis stock logo
ORGO
Organogenesis
$0.04-$0.13-$0.17-$0.17$90.77 million$86.69 million
5/6/2025Q1 2025
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
-$0.71-$0.78-$0.07-$0.78$3.24 millionN/A
5/5/2025Q1 2025
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
-$0.44-$0.50-$0.06-$0.50$18.12 million$14.75 million
4/24/2025Q1 2025
Indivior PLC stock logo
INDV
Indivior
$0.22$0.41+$0.19$0.38$240.13 million$266.00 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
N/AN/AN/AN/AN/A
Indivior PLC stock logo
INDV
Indivior
N/AN/AN/AN/AN/A
Organogenesis stock logo
ORGO
Organogenesis
N/AN/AN/AN/AN/A
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
N/A
9.56
9.56
Indivior PLC stock logo
INDV
Indivior
N/A
0.88
0.72
Organogenesis stock logo
ORGO
Organogenesis
N/A
4.12
3.67
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
0.02
4.11
4.11

Institutional Ownership

CompanyInstitutional Ownership
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
92.92%
Indivior PLC stock logo
INDV
Indivior
60.33%
Organogenesis stock logo
ORGO
Organogenesis
49.57%
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
89.06%

Insider Ownership

CompanyInsider Ownership
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
12.50%
Indivior PLC stock logo
INDV
Indivior
N/A
Organogenesis stock logo
ORGO
Organogenesis
33.00%
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
8.43%
CompanyEmployeesShares OutstandingFree FloatOptionable
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
430145.28 million127.12 millionOptionable
Indivior PLC stock logo
INDV
Indivior
1,051N/AN/ANot Optionable
Organogenesis stock logo
ORGO
Organogenesis
950126.85 million84.99 millionOptionable
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
400406.49 million372.23 millionOptionable

Recent News About These Companies

Recursion Pharmaceuticals (RXRX) Drops on Profit-Taking
10 Stocks Crash Hard Alongside Wall Street
What's Happening With RXRX Stock?

New MarketBeat Followers Over Time

Media Sentiment Over Time

Denali Therapeutics stock logo

Denali Therapeutics NASDAQ:DNLI

$15.00 +0.67 (+4.68%)
Closing price 07/9/2025 04:00 PM Eastern
Extended Trading
$15.22 +0.22 (+1.43%)
As of 07/9/2025 06:16 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Indivior stock logo

Indivior NASDAQ:INDV

$15.14 -0.03 (-0.20%)
Closing price 07/9/2025 04:00 PM Eastern
Extended Trading
$15.14 0.00 (0.00%)
As of 04:53 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

Organogenesis stock logo

Organogenesis NASDAQ:ORGO

$4.46 -0.17 (-3.67%)
Closing price 07/9/2025 04:00 PM Eastern
Extended Trading
$4.54 +0.08 (+1.68%)
As of 04:06 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage. Its products also include FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; PuraPly MZ, a micronized particulate version of PuraPly for the management of open wounds in the surgical setting; and CYGNUS Dual, a dehydrated placental tissue preserved to retain the ECM scaffold. The company's pipeline products include ReNu, a cryopreserved suspension used to support healing of soft tissues; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales representives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.

Recursion Pharmaceuticals stock logo

Recursion Pharmaceuticals NASDAQ:RXRX

$5.59 +0.23 (+4.29%)
Closing price 07/9/2025 04:00 PM Eastern
Extended Trading
$5.70 +0.11 (+1.97%)
As of 04:57 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.